Kiadis Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Kiadis Pharma's estimated annual revenue is currently $8.5M per year.
- Kiadis Pharma's estimated revenue per employee is $155,000
Employee Data
- Kiadis Pharma has 55 Employees.
- Kiadis Pharma grew their employee count by -34% last year.
Kiadis Pharma's People
| Name | Title | Email/Phone |
|---|
Kiadis Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 72 | 6% | N/A | N/A |
#2 | $8.1M | 52 | 86% | N/A | N/A |
#3 | $2.6M | 17 | 31% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $4.5M | 29 | -12% | N/A | N/A |
#6 | $1.4M | 9 | 29% | N/A | N/A |
#7 | $36.4M | 235 | -20% | N/A | N/A |
#8 | $0.6M | 4 | -56% | N/A | N/A |
#9 | $2M | 13 | 0% | N/A | N/A |
#10 | $8.5M | 55 | -34% | N/A | N/A |
What Is Kiadis Pharma?
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Kiadis Pharma is committed to developing innovative and potentially life'saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.
keywords:N/A
N/A
Total Funding
55
Number of Employees
$8.5M
Revenue (est)
-34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kiadis Pharma News
Kiadis Pharma; Cytovia Therapeutics; Nkarta, Inc; Fate Therapeutics; EMERcell; Glycostem; Phio Pharmaceuticals, Innate Pharma, Inc...
... Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and Medexus Pharma, Inc. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics...
Bluebird Bio; Novartis; Kiadis Pharma; Acceleron Pharma. Alpha Thalassemia Market Breakdown by Type: Iron Chelating Drugs; Gene Therapy.
Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be held at 15:00 CEST on 28 June 2021. Pursuant to tempor ...
Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders ("AGM”) will be held at 15:00 CEST on 28 June 2021. ...
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.7M | 55 | 38% | N/A |
#2 | $7.2M | 55 | -4% | N/A |
#3 | $6.4M | 55 | 38% | N/A |
#4 | $10.1M | 55 | 34% | N/A |
#5 | $3.5M | 55 | 6% | N/A |